[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fecal-microbiota-transplantation-fmt\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fecal-microbiota-transplantation-fmt":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,41,69,95,121,153],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100644021","phase-1-fecal-transplantation-in-hidradenitis-suppurativa--a-pilot-study-100644021",false,"NCT07668713","FEcal tranSplantation in HidradeniTIs suppuratiVA : a piLot Study","FESTIVAL","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patient with Hurley HS II (moderate severity) or III (very severe)\n* Axillomammary (LC1) or gluteal (LC3) phenotype with at least 4 inflammatory lesions: inflammatory nodule, abscess or active fistula\n* Having presented at least one relapse to a well-conducted medical treatment as proposed by the 2019 French Dermatology Society evidence center recommendations (broad-spectrum antibiotic therapy for 15 to 21 days followed by prophylactic treatment with doxycycline or cotrimoxazole). A relapse is defined as the occurrence of a new attack within 3 months of the introduction of treatment.\n\nExclusion Criteria:\n\n* Allergy or contraindication to amoxicillin-clavulanic acid\n* Patient having received biomedication in the 3 months prior to inclusion\n* Patient suffering from another inflammatory disease (IBD, inflammatory rheumatism, auto-inflammatory disease)\n* Concomitant Clostridioides Difficile infection\n* Immunocompromised patients\n* HIV infection and active HBV\u002FHCV hepatitis\n* No health insurance\n* Pregnant or breast-feeding women\n* Patients already included in a biomedical research study other than an observational study (e.g. registry, cohort)\n* Patients under guardianship\u002Fcuratorship\u002Flegal protection","ALL","18 Years",{"count":19,"type":20},24,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The medical and surgical treatment of hidradenitis suppurativa (HS) remains difficult to date. The search for new therapies for HS is a major challenge. The pathophysiology of HS, the similarities with Crohn's disease and the data in the literature suggest a role for the digestive flora in HS. The role of the intestinal microbiota has now been clearly demonstrated in the pathophysiology of chronic inflammatory bowel disease (IBD), and is suspected in many other diseases. Fecal microbiota transplantation (FMT) is the gold-standard treatment for recurrent Clostridioides Difficile infection, and is being investigated in a wide range of conditions. Our hypothesis is that FMT would improve inflammatory lesions of HS by modifying patients' digestive microbiota.\n\nTranslated with DeepL.com (free version)",[26,27],"Hidradenitis Suppurativa (HS)","Fecal Microbiota Transplantation (FMT)","NOT_YET_RECRUITING","2026-06-23",{"date":31,"type":32},"2026-06-25","ACTUAL",{"date":34,"type":20},"2026-06-01",{"date":36,"type":20},"2031-06",{"name":38,"class":39},"University Hospital, Clermont-Ferrand","OTHER",7,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100633941","phase-2-intestinal-microbiota-transplantation-for-treating-advanced-tumor-cachexia-100633941","NCT07533227","Intestinal Microbiota Transplantation for Treating Advanced Tumor Cachexia","Intestinal Microbiota Transplantation for Treating Advanced Tumor Cachexia: A Prospective, Multicenter, Single-arm, Phase II Clinical Study","FMT-CACH","Inclusion Criteria:\n\n1. Pre-advanced or advanced tumor cachexia stage.\n2. Age ≥ 18 years old, ECOG score 0-2, expected survival \\> 3 months.\n3. Patients with gastric cancer, colorectal cancer, or lung cancer who have received second-line or higher treatment.\n4. No FMT treatment in the past six months.\n\nExclusion Criteria:\n\n1. Any condition that affects gastrointestinal absorption, such as difficulty in swallowing, malabsorption, or uncontrollable vomiting; undergoing tube feeding or parenteral nutrition.\n2. Neurotic anorexia, anorexia caused by mental illness, or difficulty in eating due to pain.\n3. Acquired immunodeficiency syndrome.\n4. Currently taking or planning to take other drugs that increase appetite or weight, such as adrenal corticosteroids (except for short-term use of dexamethasone during chemotherapy), androgens, progestogens, salidroside, olanzapine, and anamorin or other appetite stimulants.\n5. Patients with Cushing's syndrome, adrenal or pituitary insufficiency; patients with difficult-to-control diabetes.\n6. Current imaging or clinical manifestations of gastrointestinal obstruction.\n7. Current uncontrolled coexisting diseases, including but not limited to decompensated cirrhosis, renal failure, uncontrolled metabolic disorders, severe active peptic ulcer disease or gastritis, or mental illnesses\u002Fsocietal conditions that may limit patient compliance with study requirements or affect the patient's ability to provide written informed consent.\n8. Within 12 months prior to the first administration, there was unstable angina pectoris, myocardial infarction, congestive heart failure (grade 2 or above according to the New York Heart Association functional classification), or vascular diseases (such as aneurysms with a risk of rupture), or other cardiac damages that may affect the safety evaluation of the study drug (such as poorly controlled arrhythmias, myocardial ischemia); within 6 months prior to the first administration, there was esophageal-gastric varices, severe ulcers, gastrointestinal perforation and\u002For fistula history, history of gastrointestinal obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), intra-abdominal abscess or history of acute gastrointestinal bleeding.\n9. Within 4 weeks prior to the first administration, a serious infection occurred, including but not limited to conditions requiring hospitalization.",{"count":50,"type":20},66,[52],"PHASE2","This project is a prospective, multicenter, single-arm, phase II clinical study aimed at evaluating the efficacy and safety of fecal microbiota transplantation (FMT) in treating advanced tumor cachexia.",[55,27],"Cachexia; Cancer",[57,58,59],"cachexia","FMT","Fecal Microbiota Transplantation","2026-04-14",{"date":62,"type":32},"2026-04-16",{"date":64,"type":20},"2026-05-01",{"date":66,"type":20},"2027-05-01",{"name":68,"class":39},"Hua Jiang",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":94},"100622771","the-safety-and-efficacy-of-fecal-microbiota-transplantation-combined-with-nutritional-intervention-in-the-treatment-of-functional-constipationa-pilot-study-100622771","NCT07387952","The Safety and Efficacy of Fecal Microbiota Transplantation Combined With Nutritional Intervention in the Treatment of Functional Constipation：a Pilot Study","Inclusion Criteria:\n\n1. Age: 18 to 70.\n2. Diagnostic criteria: Functional constipation (FC) in accordance with Rome IV criteria, which should meet the following conditions:\n\n   * Symptom requirements: The following at least 2 items should occur in ≥25% of bowel movements: a. Straining during defecation; b. Hard stool (Bristol Stool Classification score 1-2); c. Feeling of incomplete evacuation; d. Rectal obstruction sensation; e. Need for finger assistance during defecation; f. Spontaneous bowel movements \\\u003C3 times per week.\n   * It is rare to have loose stools without laxatives.\n   * Exclusion of irritable bowel syndrome (IBS): IBS diagnosis criteria not meeting Rome IV.\n   * Disease course requirements: Symptoms persist for at least 6 months and meet the above criteria within the last 3 months.\n3. Traditional treatment methods (dietary intervention, at least two laxatives or probiotics) are ineffective.\n\nExclusion Criteria:\n\n1. Pregnancy or lactation.\n2. Unable to take the intervention product or complete the examination as required.\n3. Language expression disorder or mental illness.\n4. Physical examination showed severe liver and kidney dysfunction.\n5. Acute gastrointestinal disease within 4 weeks.\n6. Constipation caused by surgery in the past 4 weeks.\n7. History or abnormal examination: cancer, severe enteritis, intestinal obstruction, inflammatory bowel disease, hypothyroidism, mental illness, stroke, heart disease, cirrhosis, renal failure, hematopoietic system diseases, organic bowel disease suggested by colonoscopy or imaging.\n8. Participation in other clinical trials within 3 months prior to enrollment.\n9. Other health problems are not suitable for participation in the study.","70 Years",{"count":77,"type":20},5,[79],"NA","Chronic constipation is a common gastrointestinal disease with a global prevalence of about 15%, significantly affecting daily life and quality of life. Traditional treatments primarily rely on laxatives, which may lead to adverse effects with prolonged use, while surgical interventions have limited patient acceptance. Recent studies indicate that gut microbiota therapies-including probiotics, prebiotics, synbiotics, postbiotics, and fecal microbiota transplantation (FMT)-can effectively manage chronic constipation. This study aims to investigate the safety and efficacy of FMT combined with a prebiotic nutritional intervention (using a co-localization strategy) in the treatment of functional constipation. Additionally, the investigators will explore changes in fecal microbiota and metabolomic profiles following the treatment.",[82,27,83],"Constipation - Functional","Chronic Constipation","RECRUITING","2026-01-27",{"date":87,"type":32},"2026-02-04",{"date":89,"type":32},"2025-07-30",{"date":91,"type":20},"2026-12-31",{"name":93,"class":39},"Peking Union Medical College Hospital",1,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":21,"phases":104,"briefSummary":105,"conditions":106,"keywords":110,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":94},"100617495","phase-1-a-real-world-study-of-fecal-transplants-for-cancer-therapy-side-effects-100617495","NCT07319364","A Real-World Study of Fecal Transplants for Cancer Therapy Side Effects","An Observational, Real-World Study Evaluating Fecal Microbiota Transplantation for the Prevention\u002FReduction of Chemotherapy\u002FTargeted Therapy-Induced Gastrointestinal Symptoms in Patients With Gastrointestinal Cancers.","Inclusion Criteria:\n\n1. Age ≥ 18 years, gender not restricted;\n2. Estimated survival time ≥ 3 months;\n3. Confirmed diagnosis of gastrointestinal tumors by pathological examination, including esophageal cancer, gastric cancer, colon cancer, rectal cancer, etc.;\n4. TNM staging of cancer in patients is Stage IV;\n5. Having undergone PD-1 or PD-L1 testing;\n6. Planned to receive the 4th cycle of chemotherapy\u002Ftargeted therapy;\n7. Occurrence of gastrointestinal adverse reactions (including but not limited to diarrhea, constipation, vomiting, nausea, etc.) within 3 cycles of conventional chemotherapy\u002Ftargeted therapy;\n8. Patients are able and willing to sign the informed consent form and complete follow-up;\n9. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 1-3;\n10. Use of oral\u002Fintravenous broad-spectrum antibiotics with caution within 3 days;\n11. Patients are able to swallow capsules without chewing;\n12. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 1-3;\n13. Laboratory test results during the screening period indicate that the subjects have sufficient organ function.\n\nExclusion Criteria:\n\n1. Patients with major organ dysfunction or even failure, including but not limited to cardiac insufficiency or heart failure, renal insufficiency or renal failure, and hepatic insufficiency\u002Fhepatic failure;\n2. Uncontrolled or severe infections;\n3. Known history of psychotropic substance abuse, alcoholism, and drug abuse;\n4. Patients with severe infections complicated with septicemia or sepsis;\n5. Patients with a history of severe allergic reactions or a known allergy to the components of liquid live bacteria enteric-coated capsules;\n6. Patients with active viral infections;\n7. Female subjects with a positive pregnancy test, lactating female subjects, and women of childbearing age who refuse to use contraceptive measures during the entire observation period (15 weeks);\n8. Patients with gastrointestinal perforation and\u002For fistula;\n9. Other conditions deemed unsuitable for enrollment by the investigator.",{"count":103,"type":20},90,[23],"The goal of this clinical trial is to learn if fecal microbiota transplantation can treat in Gastrointestinal cancer patients with chemotherapy \u002F targeted gastrointestinal symptoms. The main question it aims to answer is: To evaluate the effect of fecal microbiota transplantation (FMT) on gastrointestinal tract in patients with gastrointestinal tumors.",[27,107,108,109],"Gastrointestinal Neoplasms","Antineoplastic Agents","Drug-related Side Effects and Adverse Reactions",[59,107,108,111],"Drug-Related Side Effects and Adverse Reactions","2025-12-21",{"date":114,"type":32},"2026-01-06",{"date":116,"type":32},"2025-09-01",{"date":118,"type":20},"2026-09-01",{"name":120,"class":39},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":21,"phases":131,"briefSummary":132,"conditions":133,"keywords":139,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":4},"100602206","stop-cdi-efficacy-of-fecal-microbiota-transplantation-vs-fidaxomicin-vs-vancomycin-in-treating-and-preventing-relapse-of-clostridioides-difficile-infection-100602206","NCT07120490","STOP-CDI: Efficacy of Fecal Microbiota Transplantation vs Fidaxomicin vs Vancomycin in Treating and Preventing Relapse of Clostridioides Difficile Infection","Multicenter, Randomized, Open-label, Three-arm Study on the Efficacy of Fecal Microbiota Transplantation vs Fidaxomicin vs Vancomycin in the Treatment and Relapse Prophylaxis of Clostridioides Difficile Infection. STOP-CDI Study","STOP-CDI","Inclusion Criteria:\n\n* Individuals aged 65 years or older OR individuals aged 18 to 64 years who meet at least one of the following criteria:\n* Presence of at least two comorbid chronic diseases from the groups of cardiovascular diseases, respiratory system diseases, gastrointestinal diseases, autoimmune diseases, cancers, chronic kidney and genitourinary diseases, immunodeficiencies, diabetes, and metabolic diseases,\n* Previous episodes of CDI,\n* Healthcare-associated CDI and\u002For hospitalization within the last three months,\n* Concurrent use of antibiotics other than CDI treatment after CDI diagnosis,\n* Use of proton pump inhibitors (PPIs) started during or after CDI diagnosis.\n* Documented Clostridioides difficile infection, defined according to ESCMID as:\n\nDiagnosis of diarrhea associated with C. difficile defined by:\n\n* \\> 3 unformed stools (or \\>200 ml of unformed stool in patients with stool collection devices) within 24 hours before randomization AND\n* Clinical signs consistent with CDI and microbiological evidence of free C. difficile toxins in an enzyme immunoassay (EIA) without justified evidence of another cause of diarrhea OR\n* Clinical picture consistent with CDI and positive nucleic acid amplification test (NAAT; PCR) preferably with low cycle threshold (Ct) value, or positive toxigenic C. difficile culture OR\n* Pseudomembranous colitis diagnosed during endoscopy or colectomy combined with a positive test for toxigenic C. difficile.\n* No more than 24 hours of prior treatment with vancomycin, metronidazole, or fidaxomicin.\n* Absolute neutrophil count in peripheral blood within 3 days before intervention \\> 500\u002Fµl.\n* Ability to swallow large capsules (using test capsules) or no contraindications for FMT via nasojejunal tube, gastroscopy, colonoscopy, or rectal enema.\n* Provided informed consent for participation in the clinical study.\n\nExclusion Criteria:\n\n* Lack of consent to participate in the study or absence of logical contact without possibility of obtaining consent from an authorized person,\n* More than 24 hours of prior treatment with vancomycin, metronidazole, or fidaxomicin,\n* On the day of inclusion (up to 3 days before starting intervention) absolute neutrophil count in blood \\\u003C500 cells\u002Fµl or expected drop to this level within the next 2 days,\n* Diagnosed HIV infection with CD4 lymphocyte count \\\u003C250 cells\u002Fµl,\n* Inability to swallow large capsules (failed test capsule use) or contraindications for FMT via upper or lower gastrointestinal tract, including gastrointestinal perforation, anal atresia, discontinuity of the gastrointestinal tract, and others,\n* Known presence of other pathogens in stool known to cause diarrhea,\n* Life expectancy \\\u003C3 months,\n* Life-threatening CDI (fulminant at diagnosis - especially with septic shock),\n* Total or subtotal colectomy, ileostomy, or colostomy,\n* Unwillingness or inability to comply with protocol requirements, including any condition (physical, mental, or social) that may affect the participant's ability to adhere to the protocol.",{"count":130,"type":20},424,[79],"The STOP-CDI study is a multicenter, randomized, open-label, three-arm clinical trial comparing the efficacy of fecal microbiota transplantation (FMT) preceded by vancomycin, fidaxomicin monotherapy, and standard-of-care vancomycin in preventing recurrence of Clostridioides difficile infection (CDI) in high-risk adult patients.\n\nCDI is a common healthcare-associated infection with rising incidence and high recurrence rates, particularly in elderly and immunocompromised individuals. While current guidelines recommend fidaxomicin as first-line therapy, its availability and reimbursement remain limited in some healthcare systems. FMT, although effective, is not widely implemented as first-line treatment. This study addresses the need for comparative, real-world data to inform treatment decisions for patients at high risk of severe or recurrent CDI.\n\nEligible participants include adults aged ≥65 years or younger patients with specific risk factors such as multiple comorbidities, prior CDI episodes, recent hospitalization, use of non-CDI antibiotics, or PPI therapy. Participants will be randomized in a 2:1:1 ratio to one of three treatment arms: (1) vancomycin plus FMT, (2) fidaxomicin, or (3) vancomycin alone. FMT is administered via capsules or, if necessary, alternative endoscopic routes.\n\nThe primary endpoint is CDI recurrence within 12 weeks following the initial treatment. Secondary endpoints include clinical cure, safety, and global cure. Exploratory analyses will assess microbiome changes and potential genomic predictors of response. A total of 424 participants will be enrolled across 10 clinical sites in Poland.\n\nThe study aims to provide robust, comparative evidence to support clinical guidelines and improve outcomes for patients with CDI, particularly in healthcare systems with limited access to novel therapies.",[134,135,27,136,137,138],"Clostridioides Difficile Infection","Clostridioides Difficile Infection Recurrence","Comparative Effectiveness of CDI Treatments","Fidaxomicin","Vancomycin",[140,141,142,137,138,143],"Clostridioides difficile","CDI","Fecal microbiota transplantation","Recurrent infection","2025-08-06",{"date":146,"type":32},"2025-08-13",{"date":148,"type":20},"2025-10",{"date":150,"type":20},"2027-04-30",{"name":152,"class":39},"Medical University of Warsaw",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":16,"minAge":161,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":21,"phases":164,"briefSummary":165,"conditions":166,"keywords":168,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":175,"leadSponsor":177,"locationsCount":94},"100601036","phase-2-open-label-phase-iia-trial-evaluating-the-effect-and-safety-of-transplantation-of-fecal-microbiota-in-children-with-autism-spectrum-disorders-and-gastrointestinal-symptoms-100601036","NCT07105267","Open Label Phase IIa Trial Evaluating the Effect and Safety of Transplantation of Fecal Microbiota in Children With Autism Spectrum Disorders and Gastrointestinal Symptoms","A Proof of Concept Study : Open Label Phase IIa Trial Evaluating the Effect and Safety of Transplantation of Fecal Microbiota in Children With Autism Spectrum Disorders and Gastrointestinal Symptoms","FELICITA","Inclusion Criteria:\n\n* ASD diagnosis based on DSM-5 criteria\n* Gastrointestinal symptoms: at least a score of 5 on 1 of the 5 GSRS domains (diarrhea, abdominal pain, constipation, indigestion, reflux) for over a period of 1 year or more\n* Age between 36 and 72 months\n* Consent from all legal guardians\n* Social insurance affiliation\n\nExclusion Criteria:\n\n* Severe intellectual deficit (IQ\\\u003C30) or another uncontrolled comorbidity (e.g. epilepsy)\n* Recent change in ASD global care (cognitive behavioral therapy 6 weeks before inclusion)\n* Actual or past psychotropic medication\n* Contraindications to colon preparation (Picoprep®) and\u002For to Meopa)\n* Severe or uncontrolled gastrointestinal symptoms (e.g. urgent treatment needed)\n* Undernutrition (age related BMI \\\u003C 3rd percentile)\n* Inflammatory bowel disease\n* Exclusive diet (gluten- or sugar-free)\n* Rectal enema contraindication\n* Antibiotic or antifungal therapy 3 months before inclusion\n* Probiotics 2 months before inclusion or FMT 12 months before inclusion\n* Vancomycin or Picoprep® or Meopa (including excipients) known allergy or intolerance Experimental therapeutic trial participation 3 months before inclusion","36 Months","72 Months",{"count":77,"type":20},[52],"Autism Spectrum Disorders (ASD), affect approximately 1% of the general population and are characterized by impairments in social communication associated with repetitive\u002Fstereotyped behaviors. Approximately one-third of these patients display gastrointestinal (GI) symptoms, and a growing number of studies suggest abnormalities of gut microbiota in ASD. Gut microbiota and the brain interact through complex pathways. Preliminary evidence in adults with ASD suggests that modulation of the gut microbiota by probiotics and\u002For prebiotics and more recently by fecal microbiota transplantation could improve GI symptoms but also socio-communication deficit, with persistent improvement at year 2.",[167,27],"Autism Spectrum Disorder",[169,58,170],"Austim Spectrum Disorder","gastrointestinal symptom,","2025-07-29",{"date":173,"type":32},"2025-08-05",{"date":116,"type":20},{"date":176,"type":20},"2027-04-01",{"name":178,"class":39},"Assistance Publique - Hôpitaux de Paris"]